Another study exploring programmed death ligand 1 (PD-L1) expression in a wide range of non–ccRCC identified PD-L1 overexpression in tumor-infiltrating immune cells in 90% of tRCC cases [11]. This evidence concerns the gene CD274 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.